Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03661996 · ClinicalTrials.gov registry record · Phase 3
An Open-label, 8-week Safety, Efficacy, and Assessment of Cooling Methods for Administration of CNTX-4975-05 for Knee OA
A Phase 3 study, sponsored by Centrexion Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 854
- Enrollment target
NCT03661996: Completed Phase 3 study, sponsored by Centrexion Therapeutics.
NCT03661996 is a Phase 3 study that has completed, run by Centrexion Therapeutics. The registered enrollment target is 854 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03661996, a Phase 3 study, has completed, sponsored by Centrexion Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 854 participants
- Enrollment target
Study Summary
An Open-label, 8-Week Study to Compare the Comfort and Ease of Use of Five Different Treatment Regimens for CNTX 4975-05 Intra-articular Injection in Subjects with Chronic, Moderate-to-Severe Osteoarthritis Knee Pain.
Primary Outcome
A composite score was calculated for each of the 5 treatment regimens by summing the scores of three assessments: (1) procedure pain 30 minutes after injection of CNTX-4975-05 on a 0-4 scale, 0 was best indicating no procedure pain, 4 was worst indicating severe procedure pain; (2) assessment of subjects' satisfaction with the regimen on a scale of 1 (completely dissatisfied) to 7 (completely satisfied), 1 was worst and 7 was best; and (3) assessment of investigators' satisfaction with the regim
Interventions
- DRUG CNTX-4975-05
- DRUG Lidocaine without epinephrine
- DEVICE ElastoGel
- DEVICE Breg Ice Water Pump
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 854 participants |
| Start Date | 2018-09-18 |
| Est. Completion | 2019-10-22 |
| Phase | Phase 3 |
What the finished NCT03661996 record still lists
NCT03661996 is an interventional study that assigns participants to a tested intervention. The registered 854 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher).
The record links to 0 conditions, and to 4 interventions - of which CNTX-4975-05 is the first listed.
NCT03661996 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03661996 about?
NCT03661996 is a clinical study titled "An Open-label, 8-week Safety, Efficacy, and Assessment of Cooling Methods for Administration of CNTX-4975-05 for Knee OA". An Open-label, 8-Week Study to Compare the Comfort and Ease of Use of Five Different Treatment Regimens for CNTX 4975-05 Intra-articular Injection in Subjects with Chronic, Moderate-to-Severe Osteoarthritis Knee Pain.
What is the current status of trial NCT03661996?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 854 participants. The study started on 2018-09-18. Estimated completion is 2019-10-22.
What interventions are being tested in trial NCT03661996?
The interventions under investigation include: CNTX-4975-05 (DRUG), Lidocaine without epinephrine (DRUG), ElastoGel (DEVICE), Breg Ice Water Pump (DEVICE).
Who is sponsoring clinical trial NCT03661996?
This trial is sponsored by Centrexion Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03661996's enrollment target sits among peer trials
854 384th of 2000 higher than 1,616 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07005102 · 854 participants · Phase 2
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- NCT07290491 · 854 participants · Phase 3
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
- NCT05108896 · 855 participants · NA
Aspiration in Acute Respiratory Failure Survivors 2
- NCT06231485 · 856 participants · NA
Socialization To Enrich Participation & Support Sexuality for Young People With I/DD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI